Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205990 | 0.89 | CASP1 (0.44) | MAOBMAOACASP1CASP7HSD17B10 | |
| SCHEMBL8578811 | 0.85 | MAOB (0.64) | MAOBMAOACASP1CASP7HSD17B10 | |
| SCHEMBL1429528 | 0.81 | MAPT (0.47) | MAOBMAOACASP1CASP7HSD17B10 | |
| SCHEMBL69670 | 0.78 | MAOB (0.50) | MAOBMAOAMAPTGRM5NPSR1 | |
| SCHEMBL30451384 | 0.78 | MAOB (0.50) | MAOBMAOAMAPTGRM5NPSR1 | |
| SCHEMBL67612 | 0.78 | MAOB (0.50) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL29982629 | 0.78 | MAOB (0.54) | MAOBMAOAMAPTGRM5LMNA | |
| SCHEMBL2981516 | 0.78 | MAOB (0.74) | MAOBMAOAMAPTKDM4EGRM5 | |
| SCHEMBL16789730 | 0.78 | MAOB (0.50) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL67609 | 0.78 | MAOB (0.54) | MAOBMAOAMAPTGRM5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084784-B2 | ROR-gamma modulators and uses thereof | Piramal Enterprises Limited (IN) | 2021-08-10 | — | — | US | disclosed |
| US-20180215707-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2018-08-02 | — | — | US | disclosed |
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| EP-3122721-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015145371-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-10-01 | — | — | WO | disclosed |
| EP-2318416-B1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501733-B2 | Spiroaminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8470863-B2 | Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470863-B2 | Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2010013794-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-04 | — | — | WO | disclosed |
| US-7534801-B2 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534801-B2 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534801-B2 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| US-20050107431-A1 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005037830-A1 | PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| US-4992564-A | Preparation of 6-substituted 4-chromanones | MALLINCKRODT, INC. (US) | 1991-02-12 | — | — | US | disclosed |
| US-4918203-A | Preparation of 6-substituted 4-chromanones | MALLINCKRODT INC. | 1990-04-17 | — | — | US | disclosed |
| EP-0228172-B1 | PREPARATION OF 6-SUBSTITUTED 4-CHROMANONES | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1990-03-07 | — | — | EP | disclosed |
| EP-0228172-A1 | Preparation of 6-substituted 4-chromanones | Mallinckrodt, Inc. (a Delaware corporation) (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084784-B2 | ROR-gamma modulators and uses thereof | RORB, RORA, RORC | MAOB 2514/4885MAOA 2930/4885CASP1 2632/4885 |
| US-20180215707-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | RORB, RORA, RORC | MAOB 2514/4885MAOA 2930/4885CASP1 2632/4885 |
| US-20050107431-A1 | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | MAOB 170/4885MAOA 232/4885CASP1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.